Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) Return on Sales (2016 - 2024)

Historic Return on Sales for Spyre Therapeutics (SYRE) over the last 9 years, with Q1 2024 value amounting to 529.4%.

  • Spyre Therapeutics' Return on Sales fell 4363600.0% to 529.4% in Q1 2024 from the same period last year, while for Mar 2024 it was 529.4%, marking a year-over-year decrease of 4626100.0%. This contributed to the annual value of 382.38% for FY2023, which is 3463900.0% down from last year.
  • Spyre Therapeutics' Return on Sales amounted to 529.4% in Q1 2024, which was down 4363600.0% from 382.38% recorded in Q4 2023.
  • Spyre Therapeutics' Return on Sales' 5-year high stood at 0.57% during Q2 2021, with a 5-year trough of 529.4% in Q1 2024.
  • Moreover, its 4-year median value for Return on Sales was 98.92% (2022), whereas its average is 156.5%.
  • Per our database at Business Quant, Spyre Therapeutics' Return on Sales plummeted by -351500bps in 2022 and then plummeted by -4363600bps in 2024.
  • Spyre Therapeutics' Return on Sales (Quarter) stood at 5.61% in 2021, then tumbled by -1897bps to 112.04% in 2022, then crashed by -241bps to 382.38% in 2023, then plummeted by -38bps to 529.4% in 2024.
  • Its Return on Sales stands at 529.4% for Q1 2024, versus 382.38% for Q4 2023 and 279.35% for Q3 2023.